asa statement on glp 1 Perioperative management of patients taking glucagon-like peptide receptor agonists: Society for Perioperative Assessment and Quality Improvement (SPAQI) multidisciplinary consensus ASA Advises No Longer Holding

Of note, in people with advanced DKD, additional glucose-lowering beyond SGLT2 inhibition will be necessary, making GLP-1 receptor agonists valuable drugs in this population

A5: Studies in animal models have reported favorable oral and subcutaneous bioavailability for AOD9604

#GLP1 #MetabolicHealth #Innovation #MASLD #MASH #CKD #HFpEF

The side effects are mostly in the Gastrointestinal area: Nausea and vomiting Diarrhea or constipation Abdominal pain Dizziness, Tachycardia, Infections, Headaches being lesser reported

For older adults managing obesity, insulin resistance, or type 2 diabetes risk, they carry perhaps the strongest evidence base of any metabolic peptide therapy available today

It's important to note that these are animal studies, and results from animal research don't automatically translate to humans